An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.

Autor: Liang XJ; First Clinical Medical College of Southern Medical University, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China., Fu RY; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China., Wang HN; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China., Yang J; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China., Yao N; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China., Liu XD; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China., Wang L; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing Tongren Hospital, Beijing 100730, China.
Jazyk: angličtina
Zdroj: Journal of immunology research [J Immunol Res] 2021 Jun 08; Vol. 2021, pp. 5564568. Date of Electronic Publication: 2021 Jun 08 (Print Publication: 2021).
DOI: 10.1155/2021/5564568
Abstrakt: Background: Diffuse large B cell lymphoma (DLBCL) is a life-threatening malignant tumor characterized by heterogeneous clinical, phenotypic, and molecular manifestations. Given the association between immunity and tumors, identifying a suitable immune biomarker could improve DLBCL diagnosis.
Methods: We systematically searched for DLBCL gene expression microarray datasets from the GEO database. Immune-related genes (IRGs) were obtained from the ImmPort database, and 318 transcription factor (TF) targets in cancer were retrieved from the Cistrome Cancer database. An immune-related classifier for DLBCL prognosis was constructed using Cox regression and LASSO analysis. To assess differences in overall survival between the low- and high-risk groups, we analyzed the tumor microenvironment (TME) and immune infiltration in DLBCL using the ESTIMATE and CIBERSORT algorithms. WGCNA was applied to study the molecular mechanisms explaining the clinical significance of our immune-related classifier and TFs.
Results: Eighteen IRGs were selected to construct the classifier. The multi-IRG classifier showed powerful predictive ability. Patients with a high-risk score had poor survival. Based on the AUC for three- and five-year survival, the classifier exhibited better predictive power than clinical data. Discrepancies in overall survival between the low- and high-risk score groups might be explained by differences in immune infiltration, TME, and transcriptional regulation.
Conclusions: Our study describes a novel prognostic IRG classifier with strong predictive power in DLBCL. Our findings provide valuable guidance for further analysis of DLBCL pathogenesis and clinical treatment.
Competing Interests: The authors declare that no competing interest exists.
(Copyright © 2021 Xiao-Jie Liang et al.)
Databáze: MEDLINE